LSU was a funded Minority-Based Community Clinical Oncology Program (MB CCOP) from 1994 to 2000. Last year's submission received a favorable review but not funding. This submission is an amended application which addresses the points raised in the Summary Statement of last years submission, expands on previous descriptions of our program, and updates our current status. The proposal demonstrates our continued commitment to efforts to cancer control in the minority and under-served populations of southern Louisiana. Cancer mortality is greater than expected based on cancer incidence in Louisiana. This, in part, is due to advanced stage at diagnosis which appears to be greater among underserved and minority population. Access to care is available through a statewide hospital system for indigent populations so the barriers may be more informational than physical or financial. Outreach is what is needed and that is our strength. Although we are successful in treatment efforts, our results in minority enrollment onto cancer prevention studies and the outreach efforts which produces those enrollments will have a greater impact in cancer control. During our first year of the STAR program we enrolled 19% minority women which was roughly ten times that of the national study. This follows a similar success we enjoyed with PCPT where we had four times higher minority enrollment percentage than did the national study. When SELECT opens in September, we are confident the outreach efforts we have established will result in large numbers of African-American men joining the study. We have reversed declines in treatment and cancer control enrollments and propose continued success via the following goals: (1) Continue the collaborative efforts of our capable data management team, (2) Increase participation in STAR and add SELECT, (3) Continue to open only those studies likely to achieve accrual, (4) Increase physician incentives for support of the MB CCOP trials, (5) Carefully weigh expansion opportunities to remain focused on our goal of outreach to minority and under-served populations of Louisiana. The financial support of the National Cancer Institute will assure our continued success.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA063845-09S2
Application #
7093405
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1999-06-01
Project End
2009-05-31
Budget Start
2003-06-09
Budget End
2009-05-31
Support Year
9
Fiscal Year
2005
Total Cost
$371,101
Indirect Cost
Name
Louisiana State University Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61

Showing the most recent 10 out of 66 publications